非小细胞肺癌市场 - 全球产业规模、份额、趋势、机会和预测，按类型、按治疗、按药物类别、按最终用户、按地区和竞争进行细分，2020-2030 年预测

2024 年全球非小细胞肺癌市场价值为 198.1 亿美元，预计到 2030 年将达到 361.3 亿美元，复合年增长率为 10.51% 随着治疗方案的进步和对疾病潜在机制的更好理解，全球非小细胞肺癌 (NSCLC) 市场正在经历显着增长。非小细胞肺癌是最常见的肺癌类型，其诊断准确率已提高，可以更早发现并改善预后。随着标靶治疗和免疫疗法等个人化治疗方案的日益采用，NSCLC 管理的前景发生了巨大变化。液体活检和分子分析等先进诊断技术的出现有助于识别与癌症进展相关的基因突变和标记，从而实现更精准的治疗针对性。这刺激了针对特定基因突变的治疗方法的需求，例如 EGFR 和 ALK 抑制剂。此外，将传统化疗与免疫疗法或标靶药物结合的联合疗法已被证明可以显着改善患者的治疗效果。

市场概况
预测期	2026-2030
2024 年市场规模	198.1 亿美元
2030 年市场规模	361.3 亿美元
2025-2030 年复合年增长率	10.51％
成长最快的领域	医院和诊所
最大的市场	北美洲

全球医疗支出的增加和政府对癌症研究的资助增加进一步促进了市场的成长。免疫检查点抑制剂等新型药物的引入彻底改变了 NSCLC 患者的治疗方法。像 pembrolizumab 和 nivolumab 这样的药物在提高生存率方面表现出了良好的前景，从而导致对这些疗法的需求增加。正在进行的临床试验和治疗方法的突破继续推动市场的创新。此外，伴随诊断的进步使医疗保健提供者能够更有效地个人化治疗，从而有助于新疗法的成功。因此，製药公司和生技公司正在大力投资 NSCLC 药物开发，以满足对更有效治疗日益增长的需求。

儘管市场呈现出巨大的成长潜力，但挑战依然存在，特别是在治疗可负担性和获得先进疗法方面。新型癌症治疗方法，尤其是标靶疗法和免疫疗法成本高昂，往往会限制患者获得治疗，特别是在中低收入国家。此外，NSCLC治疗方案的复杂性可能导致不良的副作用，从而引发对患者坚持长期治疗的担忧。药品审批所涉及的监管障碍以及对更全面的临床资料的需求也阻碍了新疗法进入市场的速度。儘管存在这些挑战，但仍有大量的成长机会，特别是随着对 NSCLC 的研究不断发现新的生物标记和治疗方法。对早期检测、以患者为中心的护理以及微创疗法开发的日益关注，为未来几年製药和生物技术公司带来了重大机会。

主要市场驱动因素

诊断技术的进步

人口结构和生活方式选择的变化

主要市场挑战

治疗抵抗

主要市场趋势

精准医疗和标靶治疗

分段洞察

类型洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第五章：全球非小细胞肺癌市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按类型（腺癌、鳞状细胞癌、大细胞癌）
  • 依治疗方法（化疗、免疫治疗、放射治疗、手术、标靶治疗药物）
  • 依药物类别（血管新生抑制剂、表皮生长因子受体阻断剂、激酶抑制剂、微管稳定剂、叶酸抗代谢物、PD-1/PD-L1 抑制剂）
  • 按最终使用者（医院和诊所、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第 6 章：北美非小细胞肺癌市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 加拿大
  • 墨西哥

第 7 章：欧洲非小细胞肺癌市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 英国
  • 义大利
  • 法国
  • 西班牙

第 8 章：亚太非小细胞肺癌市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 印度
  • 日本
  • 韩国
  • 澳洲

第 9 章：南美洲非小细胞肺癌市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲非小细胞肺癌市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 合併与收购

第 13 章：全球非小细胞肺癌市场：SWOT 分析

第 14 章：竞争格局

• Bayar Healthcare AG
• Eli Lilly & Co.
• Biogen Inc
• Merck $ Co
• AbbVie Inc
• AstraZeneca PLC
• Novartis AG
• Pfizer Inc
• Avid Bioservices Inc
• Blueprint Medicines Company

第 15 章：策略建议

第16章 调査会社について・免责事项

Global Non-Small Cell Lung Cancer Market was valued at USD 19.81 Billion in 2024 and is expected to reach USD 36.13 Billion in the forecast period with a CAGR of 10.51% through 2030. The global Non-Small Cell Lung Cancer (NSCLC) market is experiencing significant growth due to advancements in treatment options and a better understanding of the disease's underlying mechanisms. NSCLC, the most common form of lung cancer, has seen a rise in diagnostic accuracy, allowing for earlier detection and improved prognosis. With the increasing adoption of personalized treatment regimens, such as targeted therapies and immunotherapies, the landscape for NSCLC management has dramatically shifted. The emergence of advanced diagnostic technologies, including liquid biopsy and molecular profiling, has helped identify genetic mutations and markers associated with cancer progression, allowing for more accurate treatment targeting. This has fueled demand for therapies tailored to specific genetic mutations, such as EGFR and ALK inhibitors. Furthermore, combination therapies, which pair traditional chemotherapy with immunotherapies or targeted drugs, have shown to significantly improve patient outcomes.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 19.81 Billion
Market Size 2030	USD 36.13 Billion
CAGR 2025-2030	10.51%
Fastest Growing Segment	Hospitals & Clinics
Largest Market	North America

Rising healthcare expenditure globally and increased government funding for cancer research have further contributed to the market's growth. The introduction of new drug classes, such as immune checkpoint inhibitors, has revolutionized the treatment approach for NSCLC patients. Drugs like pembrolizumab and nivolumab have shown promise in increasing survival rates, leading to heightened demand for these therapies. Ongoing clinical trials and breakthroughs in treatment approaches continue to drive innovation in the market. Furthermore, advancements in companion diagnostics have enabled healthcare providers to personalize treatments more effectively, contributing to the success of new therapies. As a result, pharmaceutical companies and biotechnology firms are investing heavily in NSCLC drug development to meet the growing demand for more effective treatments.

While the market presents substantial growth potential, challenges persist, particularly in terms of treatment affordability and access to advanced therapies. The high cost of novel cancer treatments, especially targeted therapies and immunotherapies, often limits patient access, particularly in low- and middle-income countries. Moreover, the complexity of NSCLC treatment regimens can result in adverse side effects, leading to concerns about patient adherence to long-term therapies. The regulatory hurdles involved in drug approval and the need for more comprehensive clinical data are also impeding the speed at which new therapies reach the market. Despite these challenges, opportunities for growth are abundant, especially as research into NSCLC continues to uncover new biomarkers and treatment approaches. The increasing focus on early-stage detection, patient-centric care, and the development of less invasive therapies presents significant opportunities for pharmaceutical and biotechnology companies in the coming years.

Key Market Drivers

Advances in Diagnostic Technologies

Advances in diagnostic technologies are playing a crucial role in driving the growth of the global Non-Small Cell Lung Cancer (NSCLC) market. Early and accurate detection of NSCLC significantly impacts treatment outcomes and survival rates. Traditional diagnostic methods, such as X-rays and CT scans, are now complemented by more advanced technologies, including high-resolution imaging, molecular profiling, and next-generation sequencing (NGS). These innovations allow for more precise tumor characterization, enabling physicians to identify specific genetic mutations and alterations in NSCLC tumors, such as EGFR, ALK, and ROS1 mutations, which can be targeted by specific therapies. According to the American Cancer Society, lung cancer is the leading cause of cancer-related deaths in the United States, with an estimated 228,820 new cases and 135,720 deaths projected for 2020.

Liquid biopsy techniques have emerged as a significant breakthrough in NSCLC diagnostics. Liquid biopsies are non-invasive, requiring only blood samples to detect cancer-related biomarkers, including circulating tumor DNA (ctDNA) and exosomes. This method enables real-time monitoring of tumor progression, detection of resistance mutations, and evaluation of treatment efficacy. Liquid biopsy's ability to provide continuous, non-invasive updates on a patient's condition reduces the need for invasive tissue biopsies and provides valuable insights into the molecular dynamics of the tumor. A study published in the Journal of Clinical Oncology reported that integrating liquid biopsy into the clinical practice of patients with NSCLC increased actionable aberration detection rates by 42% when tissue NGS was not performed.

Immunohistochemistry (IHC) and molecular imaging techniques, such as positron emission tomography (PET), are improving the detection of early-stage tumors and providing accurate assessments of the tumor's location and size. These advanced diagnostic tools are helping to stratify patients based on their disease stage and molecular profile, facilitating the selection of personalized treatment regimens, including targeted therapies and immunotherapies. The National Lung Screening Trial (NLST) demonstrated that low-dose CT screening could reduce lung cancer mortality by 20% compared to chest X-ray, highlighting the importance of early detection.

As diagnostic technologies continue to evolve, they contribute to more effective treatment decision-making, better patient outcomes, and improved survival rates, making them a key driver in the growth of the NSCLC market.

Shifting Demographics and Lifestyle Choices

The global population is aging, with a significant rise in the elderly demographic. As NSCLC is more prevalent among older individuals, this demographic shift has led to a higher incidence of the disease. Advances in healthcare have led to increased life expectancy. However, with age, the risk of NSCLC also rises. This demographic trend is driving the demand for both diagnostic and treatment services. While the prevalence of smoking has declined in some regions, it remains a major risk factor for NSCLC. The persistence of smoking habits among certain demographic groups continues to contribute to NSCLC incidence. Environmental factors, such as exposure to second-hand smoke and occupational hazards like asbestos, play a role in NSCLC development. Demographic groups with higher exposure to these factors face an increased risk.

Genetic predisposition to NSCLC can significantly influence its occurrence. Certain demographic groups may have a higher prevalence of genetic mutations that increase susceptibility to the disease. NSCLC risk can vary among different ethnicities due to genetic differences. Understanding these demographic variations is crucial for tailored prevention and treatment strategies.

Demographic disparities in healthcare access, often related to socio-economic factors, can impact early diagnosis and timely treatment initiation. Awareness of NSCLC risk factors and early symptoms can vary among different demographic groups. This influences the stage at which patients seek medical attention. Targeted interventions to promote smoking cessation, especially among high-risk demographic groups, can contribute to a reduction in NSCLC cases. Promoting healthy lifestyle choices, such as regular exercise and a balanced diet, can reduce NSCLC risk and improve overall health within specific demographics.

Key Market Challenges

Resistance to Treatment

Challenge: One of the foremost challenges in the NSCLC market is the development of resistance to treatment. NSCLC is known for its ability to adapt and evolve, often rendering initially effective therapies ineffective over time. This resistance can occur in response to chemotherapy, targeted therapies, and immunotherapies.

NSCLC tumors exhibit a high degree of heterogeneity, meaning that different regions of the tumor may have distinct genetic profiles. This heterogeneity can result in the survival of resistant cell populations. Genetic mutations within tumors can lead to the development of resistance mechanisms. For example, mutations in the EGFR gene can lead to resistance to EGFR inhibitors. The tumor microenvironment can foster drug resistance by creating conditions that protect cancer cells from treatment-induced damage.Identifying which patients will develop resistance and when it will occur remains a significant challenge. This hampers the ability to proactively manage resistance.

Resistance to treatment not only limits the effectiveness of existing therapies but also necessitates the development of new drugs and treatment strategies. This can increase the cost and complexity of NSCLC care and hinder overall market growth.

Key Market Trends

Precision Medicine and Targeted Therapies

Precision medicine and targeted therapies have emerged as pivotal trends in the treatment of Non-Small Cell Lung Cancer (NSCLC), revolutionizing the way this disease is managed. Advances in genomic profiling have enabled the identification of specific mutations, such as EGFR, ALK, ROS1, and BRAF, which are responsible for the growth and progression of NSCLC. By targeting these mutations directly, therapies can achieve higher efficacy and fewer side effects compared to conventional chemotherapy. These treatments are tailored to the genetic makeup of an individual's tumor, allowing for more personalized and effective care. The use of targeted therapies such as tyrosine kinase inhibitors (TKIs) has demonstrated improved progression-free survival rates and overall survival in patients with specific mutations.

The increasing use of next-generation sequencing (NGS) technologies is playing a crucial role in precision medicine by facilitating the detection of a wide range of genetic alterations in NSCLC. This technology enables healthcare providers to identify actionable biomarkers that guide treatment decisions, helping to optimize patient outcomes. For instance, the development of therapies like osimertinib for EGFR-mutant NSCLC and crizotinib for ALK-positive NSCLC has significantly advanced the treatment landscape, offering patients more effective and less toxic alternatives to traditional treatments.

The trend towards precision medicine is further fueled by the growing understanding of the tumor microenvironment and its role in tumor progression and resistance mechanisms. Researchers are now focused on identifying biomarkers that can predict not only response to therapies but also the potential for resistance, enabling more proactive and adaptive treatment strategies. As these targeted therapies continue to evolve, they are expected to dominate the NSCLC market, paving the way for more precise, personalized treatment regimens tailored to the unique genetic characteristics of each patient's cancer.

Segmental Insights

Type Insights

Based on the Type, Adenocarcinoma emerged as the dominant segment in the Global Non-Small Cell Lung Cancer Market in 2024. Non-Small Cell Lung Cancer, adenocarcinoma has emerged as the dominant player. Factors such as changing smoking patterns, environmental influences, advances in diagnostics, and the availability of targeted therapies have all contributed to its prominence within the global NSCLC market. As research continues to advance and our understanding of adenocarcinoma deepens, we can expect even more tailored and effective treatments for this prevalent subtype of lung cancer. Advancements in diagnostic techniques, particularly the widespread adoption of computed tomography (CT) scans and the development of molecular testing, have facilitated the early detection of adenocarcinoma. This early detection allows for more timely intervention and potentially better treatment outcomes. One of the most significant factors contributing to adenocarcinoma's dominance is the availability of targeted therapies. Adenocarcinoma is often associated with specific genetic mutations, such as EGFR and ALK. Targeted therapies that directly address these mutations have shown remarkable efficacy in treating adenocarcinoma patients, further solidifying its position in the NSCLC market. These factors are expected to drive the growth of this segment.

Key Market Players

• Bayar Healthcare AG
• Eli Lilly & Co.
• Biogen Inc
• Merck & Co
• AbbVie Inc
• AstraZeneca PLC
• Novartis AG
• Pfizer Inc
• Avid Bioservices Inc
• Blueprint Medicines Company

Report Scope:

In this report, the Global Non-Small Cell Lung Cancer Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Small Cell Lung Cancer Market, By Type:

• Adenocarcinoma
• Squamous Cell Carcinoma
• Large Cell Carcinoma

Non-Small Cell Lung Cancer Market, By Treatment:

• Chemotherapy
• Immunotherapy
• Radiation Therapy
• Surgery
• Targeted Therapy Drugs

Non-Small Cell Lung Cancer Market, By Drug Class:

• Angiogenesis Inhibitor
• Epidermal Growth Factor Receptor Blocker
• Kinase Inhibitor
• Microtubule Stabilizer
• Folate Antimetabolites
• PD-1/ PD-L1 Inhibitor

Non-Small Cell Lung Cancer Market, By End-User:

• Hospitals & Clinics
• Others

Non-Small Cell Lung Cancer Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-Small Cell Lung Cancer Market.

Available Customizations:

Global Non-Small Cell Lung Cancer market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Drug Class
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-Small Cell Lung Cancer Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma)
  • 5.2.2. By Treatment (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, Targeted Therapy Drugs)
  • 5.2.3. By Drug Class (Angiogenesis Inhibitor, Epidermal Growth Factor Receptor Blocker, Kinase Inhibitor, Microtubule Stabilizer, Folate Antimetabolites, PD-1/ PD-L1 Inhibitor)
  • 5.2.4. By End-User (Hospitals & Clinics, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Non-Small Cell Lung Cancer Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment
  • 6.2.3. By Drug Class
  • 6.2.4. By End-User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Non-Small Cell Lung Cancer Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By Drug Class
      • 6.3.1.2.4. By End-User
  • 6.3.2. Canada Non-Small Cell Lung Cancer Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By Drug Class
      • 6.3.2.2.4. By End-User
  • 6.3.3. Mexico Non-Small Cell Lung Cancer Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By Drug Class
      • 6.3.3.2.4. By End-User

7. Europe Non-Small Cell Lung Cancer Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatment
  • 7.2.3. By Drug Class
  • 7.2.4. By End-User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Non-Small Cell Lung Cancer Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By Drug Class
      • 7.3.1.2.4. By End-User
  • 7.3.2. United Kingdom Non-Small Cell Lung Cancer Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By Drug Class
      • 7.3.2.2.4. By End-User
  • 7.3.3. Italy Non-Small Cell Lung Cancer Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By Drug Class
      • 7.3.3.2.4. By End-User
  • 7.3.4. France Non-Small Cell Lung Cancer Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By Drug Class
      • 7.3.4.2.4. By End-User
  • 7.3.5. Spain Non-Small Cell Lung Cancer Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By Drug Class
      • 7.3.5.2.4. By End-User

8. Asia-Pacific Non-Small Cell Lung Cancer Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment
  • 8.2.3. By Drug Class
  • 8.2.4. By End-User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Non-Small Cell Lung Cancer Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By Drug Class
      • 8.3.1.2.4. By End-User
  • 8.3.2. India Non-Small Cell Lung Cancer Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By Drug Class
      • 8.3.2.2.4. By End-User
  • 8.3.3. Japan Non-Small Cell Lung Cancer Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By Drug Class
      • 8.3.3.2.4. By End-User
  • 8.3.4. South Korea Non-Small Cell Lung Cancer Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By Drug Class
      • 8.3.4.2.4. By End-User
  • 8.3.5. Australia Non-Small Cell Lung Cancer Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By Drug Class
      • 8.3.5.2.4. By End-User

9. South America Non-Small Cell Lung Cancer Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment
  • 9.2.3. By Drug Class
  • 9.2.4. By End-User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Non-Small Cell Lung Cancer Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By Drug Class
      • 9.3.1.2.4. By End-User
  • 9.3.2. Argentina Non-Small Cell Lung Cancer Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By Drug Class
      • 9.3.2.2.4. By End-User
  • 9.3.3. Colombia Non-Small Cell Lung Cancer Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By Drug Class
      • 9.3.3.2.4. By End-User

10. Middle East and Africa Non-Small Cell Lung Cancer Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Treatment
  • 10.2.3. By Drug Class
  • 10.2.4. By End-User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Non-Small Cell Lung Cancer Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By Drug Class
      • 10.3.1.2.4. By End-User
  • 10.3.2. Saudi Arabia Non-Small Cell Lung Cancer Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By Drug Class
      • 10.3.2.2.4. By End-User
  • 10.3.3. UAE Non-Small Cell Lung Cancer Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By Drug Class
      • 10.3.3.2.4. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Non-Small Cell Lung Cancer Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Bayar Healthcare AG
• 14.2. Eli Lilly & Co.
• 14.3. Biogen Inc
• 14.4. Merck $ Co
• 14.5. AbbVie Inc
• 14.6. AstraZeneca PLC
• 14.7. Novartis AG
• 14.8. Pfizer Inc
• 14.9. Avid Bioservices Inc
• 14.10.Blueprint Medicines Company

15. Strategic Recommendations

16. About Us & Disclaimer